Industry News
Cell death mechanism may -- paradoxically -- enable aggressive pancreatic cells to live on
4/25/2016
New findings could lead to anti-cancer drug developments that reverse immunosuppressive environments.
Analysis of Scottish hospital records has uncovered over 11,000 potentially preventable, emergency hospital admissions for iron deficiency anaemia (IDA).
Researchers identify new mechanism to target 'undruggable' cancer gene
4/22/2016
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Young adult survivors of childhood cancer report feeling middle-aged
4/22/2016
Study finds presence or absence of chronic conditions key to health-related quality of life. Do survivors of childhood cancer return to normal health as they grow up?
Risk of liver cancer from hepatitis B persists even after clearing the virus
4/22/2016
Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer.
The cell copying machine: How daughters look like their mothers
4/22/2016
Tiny structures in our cells, called centrioles, control both cell division and motility.
The gates of serotonin: Cracking the workings of a notorious receptor
4/22/2016
The receptor is involved in many disorders, including schizophrenia, anxiety, and chemotherapy nausea.
Purdue research may expand engineered T-cell cancer treatment
4/22/2016
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list.
Immunotherapy drug shows long-lasting response in advanced melanoma, UCLA study finds
4/22/2016
Pembrolizumab shown to be less toxic than traditional treatments.UCLA researchers have found that a game-changing immunotherapy drug produces positive responses that are long-lasting and with...
Study supports evidence that Rab disruption may be effective strategy for treating multiple myeloma
4/22/2016
Roswell Park Cancer Institute (RPCI) researchers are investigating agents that target and disrupt the trafficking of monoclonal antibodies in multiple myeloma, a cancer of the bone marrow.